Therapeutic effects of leuprorelin microspheres in prostate cancer

Advanced Drug Delivery Reviews

Volumn 28, Issue 1, 1997, Pages 121-138

  Sharifi, Roohollah ^a   Ratanawong, Chirasakdi ^b   Jung, Ashley ^b   Wu, Zhi ^b   Browneller, Robert ^c   Lee, Mary ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^c TAP Holdings Inc   (United States)

^d Chicago College of Pharmacy   (United States)

Author keywords

Depot leuprolide; Leuprorelin; LHRH agonist; Microsphere; Prostate cancer; Repository formulation

Indexed keywords

DRUG DOSAGE; DRUG PRODUCTS; DRUG THERAPY; ENCAPSULATION; HORMONES; ONCOLOGY;

MICROSPHERES; PEPTIDES;

CONTROLLED DRUG DELIVERY;

ANTIANDROGEN; BENZYL ALCOHOL; BICALUTAMIDE; BUSERELIN; CETRORELIX; CLONIDINE; CYPROTERONE; DIETHYLSTILBESTROL; ERGOTAMINE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; MEGESTROL; MICROSPHERE; NILUTAMIDE; PAPAVERINE; PHENOBARBITAL; PHENTOLAMINE; PROSTAGLANDIN E1; TRIPTORELIN;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; HORMONE ACTION; HOT FLUSH; HUMAN; IMPOTENCE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; TESTIS ATROPHY;

EID: 0343488348     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00054-9     Document Type: Review

References (73)

1. Boring C.C., Squires T.S., Tong T. Cancer statistics, 1993. CA Cancer J. Clin. 43:1993;7-26.
2. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
3. Huggins C., Stevens R.E. Jr., Hodges C.V. Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43:1941;303-309.
4. Veterans Administration Cooperative Urological Research Group, Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet. 124 (1975) 1011-1017.
5. A.V. Schally, A. Arimura, D.H. Coy, Recent approaches to fertility control base on derivatives of LHRH, in: P.L. Munson, E. Diezfalusky, J. Glover, R.E. Olson (Eds.), Vitamins and Hormones. Vol 38. Harcourt Brace Jovanovich, St. Louis, pp. 257-323.
6. The Leuprolide Study Group, Leuprolide vs DES in the initial treatment of advanced prostatic cancer: a randomized prospective trial. N. Engl. J. Med. 311 (1984) 1281-1286.
7. Okada H., Heya T., Ogawa Y., Shimamoto T. One month release injectable microcapsules of a luteinizing hormone releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 244:1988;744-750.
8. Plosker G.L., Brogden R.X. Leuprorelin Drugs. 48:1994;930-967.
9. package insert.
10. unpublished information from personal communication, Robert Browneller, TAP Pharmaceuticals, 1997.
11. Sharifi R., Bruskewitz R.C., Gittleman M.C., Graham S.D., Hudson P.B., Stein B. Leuprolide acetate 22.5 mg 12 week depot formulation in the treatment of patients with advanced prostate cancer. Clin. Ther. 18:1996;647-657.
12. Sharifi R., Soloway M., Clayton M., Mounzer A., Strub M., Siami P., Lee M. Acute on Chronic effect of depot leuprolide in patients with stage D2 cancer of the prostate. Anti-Cancer Drugs. 1:1990;29-31.
13. Sharifi F., Soloway M. The Leuprolide Study Group, Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J. Urol. 143:1990;68-71.
14. Jorion J.L. Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma. J. Urol. 148:1992;1539-1540.
15. Kerle D., Williams G., Ware H., Bloom S.R. Failure of long term luteinizing hormone releasing hormone treatment for prostate cancer to suppress serum luteinizing hormone and testosterone. Brit. Med. J. 289:1984;468-470.
16. Chodak G. Luteinizing hormone-releasing hormone agonists for treatment of advanced prostate carcinoma. Urology. 33(suppl):1989;42-44.
17. Peeling W. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with DES in treatment of advanced prostate carcinoma. Urology. 33:1989;45-52.
18. Smith J.A. Jr., Glode M.L., Wettlaufer J.N., Stein B.S., Glass A.G., Max D.T., Anbar D., Jagst C.L., Murphy G.P. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology. 25:1985;106-114.
19. Bischoff W. German Leuprorelin study group, 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. J. Intern. Med. Res. 18(Suppl 1):1990;103-113.
20. O'Brien A., Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J. Int. Med. Res. 18(suppl 1):1990;103-113.
21. Catalona W.J. Management of cancer of the prostate. N. Engl. J. Med. 331:1994;996-1004.
22. Veterans Administration Cooperative Urological Research Group, Carcinoma of the prostate: treatment comparisons. J. Urol. 98 (1967) 516-22.
23. Byar D.P. Proceedings: The Veterans Administration Cooperative urological Research Group's studies of cancer of the prostate. Cancer. 32:1973;1126-1130.
24. Byar D.P., Corle D. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monograph. 7:1988;165-170.
25. 2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). Sem. Oncol. 21:1994;613-619.
26. Akaza H., Aso Y., Koiso K., Fuse H., Isurugi K., Okada K., Usami M., Kotake T., Ohashi T., Ueda T., Niijima T. Leuprorelin acetate depot: results of a multicentre Japanese trial. J. Int. Med. Res. 18(suppl 1):1990;90-102.
27. Akaza H., Usami M., Koiso K., Kotake T., Aso Y., Niimima T. TAP-144-SR Study Group, Long term clinical study on luteinizing hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. Jpn. J. Clin. Oncol. 22:1992;177-184.
28. Filicori M., Flamigni C., Cognigni G., Dellal P., Arnone R., Falbo A., Capelli M. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J. Clin. Endocrinol. Metab. 77:1993;130-133.
29. M.S. Soloway, G. Chodak, N.J. Vogelzang, N.L. Block, P.F. Schellhammer, J.A. Smith, M. Scott, G. Kennealey, T.C. Gau, for the Zoladex Prostate Study Group, Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology 37 (1991) 46-51.
30. Geller J., Albert J.D., Nachsteim D.A., Loza D.C. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or oestrogen therapy. J. Urol. 132:1984;693-696.
31. Geller J. Basis for hormonal management of advanced prostate cancer. Cancer. 71(suppl):1993;1039-1045.
32. Labrie F., Dupont A., Belanger A., Lacourciere Y., Raynaud J.P., Husson J.M., Gareau J., Fazekas A.T.A., Sandow J., Monfette G., Girard J.G., Edmond J., Houle J.G. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate. 4:1983;579-594.
33. Labrie F., Dupont A., Belanger A., Cusan L., Lacourchiere Y., Monfette G., Laberge J.G., Edmond J.P., Fazekas A.T.A., Raynaud J.P., Husson J.M. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. J. Clin. Invest. Med. 5:1982;267-275.
34. P. Labrie, A. Dupont, A. Belanger, Complete androgen blockade for the treatment of prostatic cancer, in: V.T. deVita, S. Hellman, S.A. Rosenberg (Eds.), Important Advances in Oncology. Philadelphia: J.B, Lippincott, 1985, pp. 193-200.
35. Crawford E., Eisenberger M., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A., Blumenstein B.A., Davis M.A., Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321:1989;419-424.
36. L. Denis, P. Smith, J.L. Carneiro De Moura, D. Newling, A. Bono, F. Keuppens, C. Mahler, M. Robinson, R. Sylvester, M. DePauw, K. Vermeylen, P. Ongena, Members of the EORTC GU Group, Total androgen ablation: European experience. Urol. Clin. North. Am. 18 (1991) 65-73.
37. Beland G., Elhilali M., Fradet Y., Laroche B., Ramsey E.W., Trachtenberg J., Venner P.M., Tewari H.D. Total androgen ablation: Canadian experience. Urol. Clin. North Amer. 18:1991;75-82.
38. Janknegt R.A., Abbou C.C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisset J.M., DaSilva F.C., Chisolm G., Crawford E.D., Debruyne F.M.J., Dijkman G.D., Frick J., Goedhals L., Knonagel H., Venner P.M., Paulson D.F., Walsh P.C. Orchiectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multinational double-blinded randomized trial. J. Urol. 149:1993;77-83.
39. P. Iverson, F. Rasmussen, P. Klarskow, I.J. Christensen, for the Danish Prostatic Cancer Group, Long term results of Danish prostatic cancer group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostatic cancer. Cancer 72 (Suppl.) (1993) 3851-3854.
40. C.J. Tyrrell, J.E. Altwin, F. Klippel, E. Varenhorst, G. Lunglmayr, F. Boccardo, I.M. Holdawa, J.M. Ilaefliger, J.P. Jordaan, for the International Prostate Study Group, A multicentre randomized trial comparing the luteinizing hormone-releasing hormone goserelin acetate alone and with flutamide in the teatment of advanced prostate cancer. J. Urol. 146 (1991) 1321-1326.
41. 2 adenocarcinoma of the prostate (CaP): results of NCI Intergroup Study 0105 (SWOG and ECOG) (abstract 1311). J. Urol. 157:1997;336.
42. Denis L. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice. Prostate. 27:1995;233-240.
43. Bertagna C., DeGery A., Hucher M., Francois J.P., Zaniorato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br. J. Urol. 73:1994;396-402.
44. Crawford E.D., Nabors W.L. Total androgen ablation: American experience. Urol. Clin. North Am. 18:1991;55-63.
45. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumours. Cancer. 71:1993;2782-2790.
46. Gleave M., Bruchovsky N., Bowden M., Goldenberg L., Sullivan L.D. Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumour model. J. Urol. 151:1994;457A.
47. Noble R.L. Hormonal control of growth and progression in tumours of Nb rats and a theory of action. Cancer Res. 37:1977;82-94.
48. Klotz L.H., Herr W.H., Morse M.J., Whitmore W.F. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 58:1986;2546-2550.
49. Takayana T.K., Vessella R.L., Lange P.H. Newer applications of serum prostate specific antigen in the management of prostate cancer. Semin. Oncol. 21:1994;542-553.
50. Epstein J.I., Carmichael M., Partin A.W., Walsh P.C. Is tumour volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow up. J. Urol. 149:1993;1478-1481.
51. Smith J.A. Jr. Androgen suppression by gonadotropin-releasing hormone analogue in patients with metastatic carcinoma of the prostate. J. Urol. 131:1984;1110-1111.
52. Fair W.R., Aprikian A., Sogani P., Reuter V., Whitmore W.F. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer. 71:1993;1031-1038.
53. M.S. Soloway, R. Sharifi, Z. Wajsman, D. McLeod, D.P. Wood, A. Puras-Baez, for the Lupron Depot Neoadjuvant Prostate Cancer Study Group, Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J. Urol. 154 (1995) 424-428.
54. Solomon M.H., McHugh T.A., Dorr R.P., Lee F., Siders D.B. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin. Invest. Med. 16:1993;532-538.
55. Labrie F., Dupont A., Cusan L., Gomez J., Diamond P., Koutsilieris M., Suburu R., Fradet Y., Lemay M., Tetu B., Emond J., Candas B. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med. 16:1993;499-509.
56. Schulman C.C., Sassine A.M. Neoadjuvant hormonal deprivation before radical prostatectomy. Clin. Invest. Med. 16:1993;523-531.
57. Fair W.R., Aprikian A.G., Cohen D., Sogani P., Reuter V. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin. Invest. Med. 16:1993;516-522.
58. S.L. Goldenberg, L.H. Klotz, J. Srigley, M.A.S. Jewett, D. Mador, Y. Fradet, J. Barkin, J. Chin, J.M. Paquin, N.M.J. Bullock, S. Laplante, Canadian Urologic Oncology Group, Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J. Urol. 156 (1996) 873-877.
59. Gleave M.E., Goldenberg S.L., Jones E.C., Bruchovsky N., Kinahan J., Sullivan L.D. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Sem. Urol. Oncol. 14(suppl):1996;39-47.
60. Smith J.A. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinomas of the prostate. J. Urol. 152:1994;132-134.
61. Miller J.I., Ahmann F.R. Treatment of castration-induced menopausal symptoms with low dose diethylstilboestrol in men with advanced prostate cancer. Urology. 40:1992;499-502.
62. Parra R.O., Gregory J.G. Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine. J. Urol. 143:1990;753-754.
63. Loprinzi C.L., Michalak J.C., Quella S.K., O'Fallon J.R., Hatfield A.K., Nelimark R.A., Dose A.M., Fischer T., Johnson C., Klatt N.E., Bate W.W., Rospond R.M., Oesterling J.E. Megoestrol acetate for the prevention of host flashes. N. Eng. J. Med. 331:1994;347-352.
64. Schulze H., Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J. Urol. 144:1990;934-941.
65. Boccon-Gibod L., Laudat M.H., Dugue M.A., Steg A. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur. Urol. 12:1986;400-402.
66. G.H. Jacobi, Long term results of an LHRH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with premedicated cyproterone acetate, in: H. Klosterhalfen (Ed.), Endocrine Management of Prostatic Cancer. De Gruyter, Berlin, 1988, pp. 127-137.
67. Labrie F., Dupont A., Belanger A., Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with luteinizing hormone-releasing hormone agonist. J. Urol. 138:1987;804-806.
68. Kuhn J.M., Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J.F., Costa P., Husson J.M., Dahan R., Bertagna C., Edelstein R. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321:1984;413-418.
69. Schellhammer P., Sharifi R., Block N., Soloway M., Venner P., Patterson A.L., Sarosdy M., Vogelzang N., Jones J., Kolvenbag G. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Urol. 45:1995;745-752.
70. Mahler C., Denis L. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilboestrol in the initial treatment of prostate cancer. Am. J. Clin. Oncol. 11(suppl 2):1988;S127-128.
71. Gonzalez-Bardena D., Vadillo-Buenfil M., Cortez-Morales A., Fuentes-Garcia M., Cardenas-Cornejo I., Comaru-Schally A.M., Schally A.V. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 45:1995;275-281.
72. Smith J.A. Jr., Urry R.L. Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue. J. Urol. 133:1985;612-614.
73. Rajfer J., Swerdloff R.S., Heber D.M. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment. Fertil. Steril. 42:1984;765-771.